PNTG vs. INNV, WGS, TALK, DCGO, SHCR, PIII, USPH, PRVA, GHRS, and OLMA
Should you be buying The Pennant Group stock or one of its competitors? The main competitors of The Pennant Group include InnovAge (INNV), GeneDx (WGS), Talkspace (TALK), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), U.S. Physical Therapy (USPH), Privia Health Group (PRVA), GH Research (GHRS), and Olema Pharmaceuticals (OLMA). These companies are all part of the "medical" sector.
The Pennant Group (NASDAQ:PNTG) and InnovAge (NASDAQ:INNV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment.
The Pennant Group has a net margin of 2.86% compared to InnovAge's net margin of -4.16%. The Pennant Group's return on equity of 13.42% beat InnovAge's return on equity.
In the previous week, The Pennant Group had 4 more articles in the media than InnovAge. MarketBeat recorded 8 mentions for The Pennant Group and 4 mentions for InnovAge. The Pennant Group's average media sentiment score of 0.83 beat InnovAge's score of 0.32 indicating that The Pennant Group is being referred to more favorably in the media.
The Pennant Group has higher earnings, but lower revenue than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
85.9% of The Pennant Group shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 5.8% of The Pennant Group shares are held by company insiders. Comparatively, 0.4% of InnovAge shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
The Pennant Group currently has a consensus target price of $24.00, indicating a potential upside of 4.26%. InnovAge has a consensus target price of $6.50, indicating a potential upside of 75.68%. Given InnovAge's higher possible upside, analysts plainly believe InnovAge is more favorable than The Pennant Group.
The Pennant Group has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, InnovAge has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
The Pennant Group received 34 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 44.74% of users gave The Pennant Group an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
Summary
The Pennant Group beats InnovAge on 16 of the 18 factors compared between the two stocks.
Get The Pennant Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PNTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Pennant Group Competitors List
Related Companies and Tools
